<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20250412065292N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-06-08</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>Studying the effect of montelukast in reducing pain after surgery</public_title>
      <acronym></acronym>
      <scientific_title>Investigation of Preoperative Oral Montelukast Prescription on Postoperative Pain Levels Following Zygomaticomaxillary Complex Fracture Surgery</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-08-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/83722</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: To randomly allocate 80 patients into two groups (intervention and control, each with 40 patients) and subsequently divide each group into four time-based subgroups (0, 6, 12, and 24 hours before surgery), stratified block randomization will be employed. Patients will be stratified into four layers based on age (under 50 years and 50 years and older) and gender (male/female) to ensure balance in key variables. Within each stratum, patients will be evenly assigned to the intervention and control groups using block randomization (block size of 4) via the R software. Each group will then be randomly divided into four time-based subgroups (10 patients each). The random sequence will be generated using the `blockrand` function in R and documented with a specified seed. For allocation concealment, group and timing information will be placed in opaque, sealed envelopes managed by a student. These envelopes will be opened at enrollment to determine the group and timing of drug or placebo administration. The triple-blind design ensures that patients, treating surgeons, and data analysts remain unaware of the allocations, Blinding description: In this study, a triple-blind randomized allocation will be used. Although the randomization codes will be concealed from the patient, the treating surgeon, and the data analyst (triple-blind randomized clinical trial), the dental student and the anesthesiologist will be aware of the group to which the patient has been assigned. Patients will be blinded in the following way: before the surgery, each patient will be given a glass of juice and informed that, in this study, there are two groups receiving the juice—one group receives juice containing the medication, and the other receives juice without the medication. Only the researcher will know which juice contains the drug.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Zygomaticomaxillary complex fracture.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:  At time intervals of 0, 6, 12, and 24 hours before transfer to the operating room, patients will receive a 40 mL glass of fruit juice containing 10 mg of montelukast (Abidi Pharmaceuticals) dissolved in it. Intervention 2: Control group: At different time intervals — 0, 6, 12, and 24 hours before being transferred to the operating room, patients will be given a glass of drug-free fruit juice.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The shared IPD will include deidentified data related to primary outcome measures, such as Visual Analogue Scale scores recorded every 2 hours for 12 hours postoperatively, timing of drug administration, and demographic variables (age, sex, BMI). These data will be shared upon reasonable request after publication of the main results.

When:
The deidentified data and related documents will be available starting 6 months after publication of the study results and will remain accessible for a period of 2 years following that date.

To whom:
Deidentified individual participant data and supporting documents will be shared with qualified researchers affiliated with academic institutions. Access may also be granted to researchers from non-academic organizations, such as industry or healthcare companies, upon reasonable request and subject to approval by the principal investigator.

Conditions:
Deidentified individual participant data and supporting documents will be shared only for research purposes, such as meta-analyses, secondary analyses of outcomes, or validation of findings. Requests for data access must include a detailed research proposal and will be reviewed by the principal investigator and an independent data access committee to ensure ethical use and scientific validity. Approved data will be shared via secure email or institutional data-sharing platforms under a data use agreement.

Where to obtain:
Applicants seeking access to the deidentified individual participant data and related documents should contact the principal investigator via the following communication channels:

Preferred contact method: Email

Email address: drfarrokhfarhadi@gmail.com

Postal address: Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Tabriz University of Medical Sciences, Golgasht Street, Tabriz, Iran

Phone number: +989144138028

Fax number: +984133346977

Contact person: Dr. Farokh Farhadi Shabestari, Principal Investigator

How to obtain:
To request access to the deidentified individual participant data and related documents, applicants must follow these steps:

1. Submit a Request: Send an email to the principal investigator (Dr. Farokh Farhadi Shabestari  at drfarrokhfarhadi@gmail.com, including the following:

   * A detailed research proposal outlining the objectives and intended analyses.
   * A description of how the data will be used and stored.
   * Institutional affiliation and ethical approval (if applicable).

2. Review Process:
   The research team will review requests within 2 to 4 weeks. The review will evaluate:

   * Scientific merit and relevance of the proposed project.
   * Ethical considerations and data security measures.
   * Compatibility with the original study’s consent and ethical approval.

3. Data Use Agreement:
   Approved applicants will be required to sign a Data Use Agreement (DUA) to ensure the responsible use of shared data and prevent attempts to reidentify participants.

4. Data Delivery:
   Upon signing the DUA, data will be shared securely via encrypted email or institutional file-sharing platforms within 1 week.

Estimated total time: Approximately 3 to 5 weeks from initial request to receipt of data.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Farokh Farhadi Shabestari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Dentistry, Tabriz University of Medical Sciences, Golgasht Street, Tabriz, Iran</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166614711</zip>
        <telephone>+98 41 3335 5965</telephone>
        <email>drfarrokhfarhadi@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Farokh Farhadi Shabestari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Dentistry, Tabriz University of Medical Sciences, Golgasht Street, Tabriz, Iran</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166614711</zip>
        <telephone>+98 41 3335 5965</telephone>
        <email>drfarrokhfarhadi@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>The participating patients who have zygomaticomaxillary complex fracture
Patients aged between 18 and 60 years
Patients of both sexes, male and female
Patients with a BMI of less than 30 kg/m² (non-obese)</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Preoperative use or dependence on narcotic drugs
Having peptic ulcer disease, hepatic or renal dysfunction, or psychiatric disorders
Allergy to amide local anesthetics and narcotics, and a history of seizures
Cases where the participant requires intensive care unit admission after surgery</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>S02.40</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Fracture of malar, maxillary and zygoma bones, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:  At time intervals of 0, 6, 12, and 24 hours before transfer to the operating room, patients will receive a 40 mL glass of fruit juice containing 10 mg of montelukast (Abidi Pharmaceuticals) dissolved in it.</i_keyword>
      <i_keyword>Control group: At different time intervals — 0, 6, 12, and 24 hours before being transferred to the operating room, patients will be given a glass of drug-free fruit juice.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Postoperative pain intensity score measured using the Visual Analogue Scale from 0 to 10, in patients undergoing surgery for zygomaticomaxillary complex fractures, comparing Montelukast and control groups. Timepoint: Pain intensity will be assessed immediately after recovery and every two hours for a total duration of 12 hours. Method of measurement: The outcome was measured using the Visual Analogue Scale for pain intensity.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-11-10</approval_date>
        <contact_name>Ethics Committee in Biomedical Research Faculty of Dentistry Tabriz University of Medical Sciences</contact_name>
        <contact_address>Faculty of Dentistry, Tabriz University of Medical Sciences, Golgasht St, University St Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
